Anti-HCMV activity of cidofovir in combination with antiviral compounds and immunosuppressive agents: In-vitro analyses

Antiviral Chemistry and Chemotherapy

Volumn 7, Issue 4, 1996, Pages 203-208

  Mulato, A S ^a   Cherrington, J M ^a   Chen, M S ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Cidofovir; Human cytomegalovirus (HCMV); Synergy

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; CYCLOSPORIN A; DIDANOSINE; GANCICLOVIR; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; METHOTREXATE; MYCOPHENOLIC ACID; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

EID: 0030001155     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029600700405     Document Type: Article

References (28)

1. Aduma, P., Connelly, M.C., Srinivas, R.V., and Fridland, A. (1995) Comparison of the metabolism and antiviral activity of acyclic nucleoside phosphorates. Mol Pharmacol 47: 816-822.
2. Baba, M., Ito, M., Shigeta, S., and DeClercq, E. (1984) Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella zoster virus in vitro. Antimicrob Agents Chemother 25: 515-517.
3. Cherrington, J.M., Miner, R., Hitchcock, M.J.M., Lalezari, J.P., and Drew, W.L. (1996) Susceptibility of human cytomegalovirus (HCMV) is unchanged after limited in vivo exposure to various clinical regimens of drug. J Infect Dis (in press).
4. Drew, W.L., Miner, R., Busch, D.F., Follansbee, S.E., Gullett, J., Mehalko, S.G., Gordon, S.M., Owen, W.F., Matthews, T.R., Buhles, W.C., and DeArmond, B. (1991) Prevalence of CMV resistance in patients receiving ganciclovir for serious CMV infection. J Infect Dis 163: 716-719.
5. Erice, A., Chou, S., Biron, K.K., Stanat, S.C., Balfour, H.H., and Jordan, M.C. (1989) Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 320: 289-293.
6. Forbes, B.A., Bonville, C.A., and Dock, N.L. (1990) The effects of a promoter of cell differentiation and selected hormones on human cytomegalovirus infection using an in vitro cell system. J Infect Dis 162: 39-45.
7. Freitas, V.R., Fraser-Smith, E.B., and Matthews, T.R. (1989) Increased efficiacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res 12: 205-212.
8. Ho, H.T., Woods, K.L., Bronson, H., De Boeck. H., Martin, J.C., and Hitchcock, M.J.M. (1992) Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxyl-2- (phosphonylmethoxy) propyl]cytosine. Mol Pharmacol 41: 197-202.
9. Holy, A., and Rosenberg, I. (1987) Synthesis of 9-(2-phosphonylmethoxyethyl)adenine and related compounds. Collect Czech Chem Commun 52: 2801-2809.
10. Holy, A., Rosenberg, I., and Dvorakova, H. (1989) Synthesis of (3-hydroxyl-2-phosponylmethoxypropyl) derivatives of heterocyclic bases. Collect Czech Chem Commun 54: 2470-2501.
11. Knox, K., Dobryski, W., and Carrigan, D. (1991) Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 337: 1292-1293.
12. Laskin, O.L., Stahl-Baylis, C.M., Kalman, C.M., and Rosencran, L.R. (1987) Use of ganciclovir to treat serious Cytomegalovirus infections inpatients with AIDS. J Infect Dis 155: 232-327.
13. Lathey, J.L., and Specter, S.A. (1991) Unrestricted replication of human Cytomegalovirus in hydrocortisone-treated macrophages. J Virol 65: 6371-6375.
14. MacGregor, M.P., Lucia, H.L., Vine, W., Fitzgerald, P., and Bia, F.J. (1986) Effect of cyclosporine and cortisone on the pathogenesis of primary infection with Cytomegalovirus in the guinea pig. J Infect Dis 153: 503-510.
15. Macher, A., Reichert, C., Straus, S., Longo, D., Parillo, J., Lane, H., Rook, A., Maniscewitz, J., and Quinnan, G. (1983) Death in the AIDS patients: role of Cytomegalovirus. New Eng J Med 309: 1454.
16. Manischewitz, J.F., Quinnan, G.V., Lane, H.C., and Wittek, A.E. (1990) Increased efficiacy of ganciclovir and foscarnet on Cytomegalovirus replication in vitro. Antimicrob Agents Chemother 34: 373-375.
17. Masur, H., Lane, H.C., Palestine, A., Smith, P.D., Manischewitz, J., Stevens, G., Fujikawa, L., Macher, A.M., Nusenblatt, R., Baird, B., Megill, M., Wittek, A., Quinnan, G.V., Parillo, J.E., Rook, A.H., Eron, L.J., Poretz, D.M., Goldenberg, R.I., Fauci, A.S., and Gelman, E.P. (1986) Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on serious Cytomegalovirus disease in eight immunosuppressed homosexual men. Ann Intern Med 104: 41-44.
18. Meyers, J.D., Flournoy, N., and Thomas. E.D. (1986) Risk factors for Cytomegalovirus infection after human marrow transplantation. J Infect Dis 153: 478-488.
19. Numazaki, K., Nagata, N., Sato, T., and Chiba, S. (1994) Effect of glycyrrhizin, cyclosporine A, and tumor necrosis factor α on infection of U-937 and MRC-5 cells by human Cytomegalovirus. J Leukoc Biol 55: 24-28.
20. Prichard, M.N., Aseltine, K.R., and Shipman, C., jr. (1993) MacSynergy II. Version 1.
21. Ringden, O., Lonnquist, B., Paulin, T., Ahlmen, J., Klintmalm, G., Wahren, B., and Lernestedt, J.O. (1986) Pharmacokinetics, safety, and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother 17: 373-387.
22. Roehm, N.W., Rodgers, G.H., Hatfield, S.M., and Glasebrook, A.L. (1991) An improved colonmetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Meth 142: 257-265.
23. Shanley, J.D., and Debs, R.J. (1989) The folate antagonist, methotrexate, is a potent inhibitor of murine and human cytomegalovirus in vitro. Antiviral Res 11: 99-106.
24. Snoeck, R., Andrei, G., Schols, Balzarini, J., and DeClercq, E. (1992) Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro. Eur J Clin Microbiol Infect Dis 11: 1144-1155.
25. Snoeck, R., Andrei, G., and De Clercq, E. (1995) Human cytomegalovirus (HCMV) strains selected under selective pressure of phosphonoformate (PFA) are resistant for both PFA and phosphonylmethoxyethyl (PME) derivatives in vitro. Antiviral Res 26:
26. Stanat, S.C., Reardon, J.E., Ence, A., Jordan, M., Drew, W.L., and Biron, K.K. (1991) Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother 35: 2191-2197.
27. Tanaka, J., Ogura, T., Kamiya, S., Sato, H., Yoshie, T., Ogura, H., and Hatano, M. (1984) Enhanced replication of human cytomegalovirus in human fibroblasts treated with dexamethasone. J Gen Virol 65: 1759-1767.
28. Tymes, A., Taylor, D., and Parkin, J. (1989) Cytomegalovirus and the immunodeficiency syndrome. J Antimicrob Chemother 23 (Suppl A): 89-105.